Results from a trial of an mRNA vaccine for pancreatic cancer have shown that the vaccine reduces the chance of the cancer ...

The five-year survival rate for Stage I pancreatic cancer is around 83 percent. In other good news, researchers associated ...

A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study ...

A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage ...

Pancreatic cancer is one of the deadliest types of cancer, with fewer than 13% of people diagnosed with it surviving for more ...

Memorial Sloan Kettering Cancer Center researchers have found RNA neoantigen vaccines that generate long-lived, functional ...

Adding a personalized mRNA vaccine to standard treatment could offer new hope for pancreatic cancer patients, a small yet ...

In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three ...

A personalized mRNA vaccine appeared to reduce the chances of pancreatic cancer returning after surgery, according to a study ...

Pancreatic cancer is the 10th deadliest form of cancer in the United States, according to the National Cancer Institute.

The trial would combine standard surgery and chemotherapy treatments — which are the standard of care for pancreatic cancer — with a customized mRNA vaccine. Each vaccine would be designed ...